SLRX beat EPS expectations by 68.95%
Nov 22, 2024, 11:31 PM
7.48%
What does SLRX do
Salarius Pharmaceuticals, a clinical-stage biopharmaceutical company based in Houston, Texas, focuses on developing innovative cancer treatments, including seclidemstat and SP-3164. The company went public on January 29, 2015.
Salarius Pharmaceuticals (SLRX) reported a positive EPS surprise in its most recent quarterly earnings. For the most recent quarter, Salarius Pharmaceuticals's actual EPS was -$0.76, beating the estimate of -$2.45 per share, resulting in a 68.95% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!